Shortcuts Pursued in Effort to Close Compendial Gaps
This article was originally published in The Gold Sheet
Executive Summary
Officials with FDA, the U.S. Pharmacopeia and the pharmaceutical industry are looking for a quicker way to remedy a situation underscored by the 2008 heparin crisis: the need to update hundreds, perhaps thousands of the compendial standards that the U.S. Pharmacopeia developed and FDA enforces.
You may also be interested in...
Five Years Later, Legacy Biologics Still Face ‘Next Heparin’ Risks
Several factors continue to slow efforts to modernize legacy biologics’ compendial monographs against fake ingredients like the ones someone put in heparin in 2008. Hyaluronate, the ‘poster child’ for monograph modernization; New NDAs for pancreatin create new modernization challenges; Heparin maker vertically integrates to prevent adulteration.
Fercy Warning Letter Confirms OTC Monograph Fears
Drug maker in China found to exploit gap in U.S. regulatory system, exporting OTC monograph drugs without key quality controls or registration until FDA inspection led to import suspension.
USP Told 'Big Four' Heavy Metals Should Take Priority in Compendial Revision
Go after 'big four' heavy metals first in revising outdated compendial standard, USP told. Start with arsenic, cadmium, lead and mercury, not all 31 listed metals, industry says in response to stimuli article, which would let them choose methods for meeting performance-based standards. Residual solvents chapter proposed as template. EMEA catalyst guideline lauded. Some want dosing frequency considered in setting toxicology limits.